:lick: Einfacher gehts nicht. DNAP wird explodieren :lick: - 500 Beiträge pro Seite

[McFlying]

Liebe Leute,
der nächste 1000%ler winkt hier

Es werden News erwartet, entweder heute, spätestens aber am Montag.
Danach wird DNAP nicht mehr zu halten sein.
Persönlich rechne ich mit kurzfristigen kursen von 0,05-0,10 Dollar

Es kann so einfach sein Geld an der börse zu verdienen und noch nie war eine Chance größer wie diese

Aktuell 0,015 Dollar.

In den letzten Tagen gingen größere Orders raus.

Der Hype wird aber noch kommen.

Verpasst nicht diese Gelegenheit.




USA Kürzel----DNAP


Effective September 28, 2004, the Registrant entered into an Investment Agreement (the "Biofrontera Agreement") with Biofrontera AG, a German corporation ("Biofrontera") and the shareholders of Biofrontera. Prior to entering into the investment agreement, Richard Gabriel, the Registrant`s chief executive officer and a director, and Monica Tamborini, the Registrant`s chief financial officer, each owned less than 1% of the outstanding equity securities of Biofrontera.

Pursuant to the Biofrontera Agreement, the Registrant has agreed to purchase certain Series B preferred shares of Biofrontera. The purchase of the shares would give the Registrant an equity interest of approximately 51% in Biofrontera. The purchase price of the shares is 20 million Euro, payable in monthly installments of 833,333 Euro over a period of 24 months. The transaction will not close, and the Registrant`s payment obligation does not begin, until after the effectiveness of a registration statement to be filed under the Securities Act of 1933 by the Registrant with respect to the Dutchess Agreement, described in this Current Report under the caption "Dutchess Agreement."

In the event that such registration statement does not become effective on or before February 7, 2005, the Biofrontera Agreement will terminate without liability to either party. Once the registration statement has become effective, the Registrant is obliged to consummate the acquisition of the shares, and Biofrontera will issue all of the shares to the Registrant. In the event the Registrant defaults in payment of the purchase price installments, Biofrontera has the right to redeem from the Registrant those shares as to which the purchase price has not been paid in full. In no event does Biofrontera have the right to recover the unpaid purchase price from the Registrant in cash.

The Registrant has the right to nominate two members of the six-person Biofrontera board. In addition, a representative of Biofrontera, Professor Doctor Herman Luebbert will join the Registrant`s board of directors after the closing of the transaction. If the Registrant fails to pay the full purchase price for the Biofrontera shares, the Registrant forfeits its right to appoint such board members.
It time for DNAP to pull a rabbit ( MONEY ) out of the hat .

[McFlying]

[McFlying]

Bei 0,20 ist ein Gap zu schließen

Vielleicht schon heute

[McFlying]

HOFF hat es vorgemacht

Von 0,20 Dollar in 2 Tagen über 3 Dollar

SPEA in einem Monat von 0,10 Dollar auf über 14 Dollar.

Hier winkt wohl die nächste Rakete

[McFlying]

Hier die letzte News


2 February 2005, 12:26pm ET

SARASOTA, Fla., Feb. 2 /PRNewswire-FirstCall/ -- DNAPrint genomics (BBNAP) of Sarasota, FL (the "Company") announces today that the Company and Senecio Software Inc. have been awarded a highly competitive Small Business Initiative Research (SBIR) grant by the National Institutes of Health (NIH).

The principle objective of the co-authored grant application is to create software systems that will expand DNAPrint`s technology reach to institutional, government and academic markets.

Recent federal directives require the use of multiracial classification on official forms and surveys and call for the Government to do a better job of recognizing diversity in ancestral origins. However, demographic research on race is becoming increasingly difficult given its multiple measures and the growing complexity in defining race.

As the first to enable an objective and quantitative measurement of continental and/or ethnogeographic ancestry admixture, DNAPrint`s innovative genetic testing technology (ANCESTRYbyDNA(TM) 2.5, DNAWitness(TM) 2.5, EURO-DNA(TM) 1.0, EURO-Witness(TM) 1.0) represents a logical, scientific and convenient proxy measure for institutional, government and academic researchers.

Target markets for the software system to be developed in this grant project include government and academic demographers, social scientists and policy makers.

Customers can learn more about DNAPrint`s tests for the inference of ancestry admixture at http://www.ancestrybydna.com .

About DNAPrint genomics, Inc.

DNAPrint genomics Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company introduced ANCESTRYbyDNA(TM) in the consumer market and DNAWitness(TM) in the forensic market in 2003. DNAPrint is developing products in the pharmacogenomic market and has a disease gene discovery program. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit http://www.dnaprint.com .

About Senecio Software

Mentioned Last Change
DNAP 0.0115 0.0002dollars or (1.76%)
Founded in 1992, Senecio Software Inc. is a privately held company based in Bowling Green, Ohio. The company specializes in the design and production of advanced, multi-tier, web-based systems used in the collection and analysis of social, health, market research, and demographic data. Given the rise in Internet-based commerce and the demand for online information processing solutions, Senecio`s corporate strategy has increasingly focused on the development of customized data-gathering tools used by professional survey researchers, scientists, and market analysts. Along with designing multi-tier, web-based survey software, Senecio is developing unique data gathering tools involving remote sensing and wireless communication. Senecio Software has been the recipient of numerous research grants from the U.S. government`s National Institutes of Health. Additional information about the company, its products, partnerships and research agenda can be found at http://www.senecio.com .

Funding for this research is provided through the Department of Health and Human Services Small Business Innovation Research Program, National Institutes of Health. Grant Number: 1 R43 AGO25768-01A1 - National Institute on Aging.

All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

[babe_in_the_woods]

@McFlying

nicht gleich übertreiben!

"Aktuell 0,015 Dollar." sondern Aktuell 0,0115 Dollar.

bin auch fett drin!

[TOKL]

hast du die spea bei 0,10 gekauft???

[McFlying]

Babe

Ups sorry,

hast recht, hab mich vertippt

einfach einige Ins Depot legen und bis Montag warten.
dann mit ner Schubkarre das Geld nach hause fahren

[McFlying]

Bid 0,0115

[McFlying]

Massive Käufe aus dem Ask

Ist die Pr schon da

[babe_in_the_woods]

@McFlying

wenn das Ding raufschiesst, kommt BIOM aus dem Loch!

wetten!

...und der nächste Tipp von ihm ist fällig.

[McFlying]

Babe


Was mich wundert ist, das die letzten tage so massiver kaufdruck war.

Da sind wohl schon einige eingestiegen die mehr wissen

Ich lasse mich gern überraschen.

[McFlying]

Im Ask lösen sich die MM auf

Es werden immer weniger.

Die ahnen wohl selber schon etwas

[ooy]

Der letzte Quarterly Report war eine Katastrophe, die haben bald fertig, Finger weg.
Einen RS soll es auch bald geben. Die drucken Aktien wie nochwas.

[babe_in_the_woods]

jetzt gehts rund!

bin gespannt!

[puschlm]

hallo DNAP´ler,

in USA 0,0119 bezahlt

bin seit @BIOMs tipp auch dickest investiert, und wenn sie ähnlich läuft wie so manche andere seiner empfehlungen, dann jippieeee.

good luck
puschlm

[McFlying]

Bin wieder da

Die Amis warten ebenfalls auf die News

Wir werden hier richtig Geld verdienen

Haltet die Hände auf

[McFlying]

Hier wird versucht einige Investierte rauszudrücken.
SK heute über 0,012 Dollar.
Jede Wette

Falls die News noch kommt, SK 0,05

[McFlying]

C`mon DNAP give us a afternoon PR so we can have a SUPER weekend...... then I can really enjoy the SUPER BOWL!

GOOOOOOOOOOOO PHILLY!
- - - - -
View Replies »

Advertisements
• Trade like a pro with Qcharts
• Try Livecharts free for 14 days!

« DNAP Message list | Reply to msg. |

[McFlying]

Wieder 200k aus dem Ask

[lvlover]

kannst du mal bitte mal n link geben, wo die kurse in usa zu finden sind??
danke!

[McFlying]

http://www.d-traderz.com/

ist Realtime

[lvlover]

klappt bei mir leider nicht.
auf onvista gehts wieder richtig abwärts.
das wars dann wohl, schade....

[leandro01]

Na, dann bin ich mal gespannt ob hier nur heisse Luft geblasen wurde oder ob wir Montag was sehen !!!!
Ich persönlich denke, das wars!!!!!
Wir können uns wohl erst nach dem RS und dann weiteren
6 Monaten Hoffnung auf bessere Zeiten machen....

[McFlying]

0,00115

[McFlying]

sorry

0,0115

Bid zieht an 0,011

[babe_in_the_woods]

@McFlying

hast du schon den heutigen Umsatz gesehn

[McFlying]

ist schon sehr wenig.
Alle warten wohl auf die News

[leandro01]

McFly, da kommt heute nichts mehr. Die ganzen Pusher sind auch schon längst verschwunden - guck dir den Kurs mal lieber wieder in 6 Monaten an - oder besser 2007/2008 - dann wirst du daran weitaus mehr Freude haben.
Nicht falsch verstehen, bin selber drin und hätte hier natürlich selbst gern kurzfristig die große Kohle gemacht, aber die Hoffnung müssen wir wohl begraben....

[McFlying]

0,0109 - 0,011

Müsste gleich explodieren

[McFlying]

Sag ich doch

Ask 0,0113

[McFlying]

265k at Ask

Kommt da was

[strauss]

Nein!

[leandro01]

Na McFLy, wie fühlt man sich nach so einem Tag der Ernüchterung. Ich hoffe, du hast gestern trotzdem Karneval gefeiert und deinen Frust ordentlich ertränkt.
Dein Oberguru BIOM ist natürlich auch schon längst in der Versenkung verschwunden, war wohl nicht Manns genug seine falsche Prognose einzugestehen und sorgt sich um seinen Ruf als "bester" Tippgeber auf w:o.....

[McFlying]

mal sehen, was uns der Tag heute bringt.

Wir müssten heute im grünen Bereich eröffnen

[McFlying]

Vorbörslich schon dicke Käufe aus dem Ask

Kommt die News gleich

[leandro01]

So...
die Luft ist raus !!!!
Die News waren ein Windei, nachlassender Umsatz, langsamer Kursrückgang und anstehender RS. Das wars für´s erste
See you at 0,003

[McFlying]

Locker bleiben

Es kommt immer so, wie man es nicht glaubt

Hoff ist auch ausgebrochen, wo keiner mehr dran geglaubt hat.
VOCL nun auch.
Das Kind schaukelt sich schon von alleine

[leandro01]

...und weiter gehts runter. Aktuell 0,010 in USA,..und der letzte Gläubige im Thread hier ist mittlerweile auch "ausgeflogen"......
Also, dann machts gut - bis in frühestens in 6 Monaten.....
Gruß und tschüß
Leo

[McFlying]

ich bin noch da

Ab und zu muss auch ich noch arbeiten

Fragt sich nur wie lange noch

[McFlying]

ask 0,011

Hier kommt noch was

[strauss]

Stimmt, es geht weiter runter

war ja eh nur ein Miniumsatz zu ,11

[puschlm]

News !!!


DNAPrint Teams With Victoria Police Forensic Services Center to Win Australian ISL Grant
Thursday February 10, 8:30 am ET


SARASOTA, Fla., Feb. 10 /PRNewswire-FirstCall/ -- DNAPrint genomics (OTC Bulletin Board: DNAP - News; the "Company") announces today that it has teamed with Victoria University in Melbourne, Australia and the Victoria Police Forensic Science Services Centre (VFSC) to win a highly competitive 2004 Australian International Science Linkages (ISL) grant.
ADVERTISEMENT


The grant was authored by Victoria University`s Dr. Swati Baindur-Hudson, with the assistance of DNAPrint scientists, to support the validation and potential integration of the Company`s RETINOME(TM) test at the VFSC. The ISL program supports Australian scientists, from both the public and private sectors, to collaborate with international partners on leading-edge science and technology in order to contribute to Australia`s economic, social and environmental wellbeing.

The subject of the grant, DNAPrint`s RETINOME(TM) test, is a genetic assay for the inference of iris color from DNA. When used with other DNAPrint products for the inference of continental (DNAWitness(TM) 2.5) and ethno geographic ancestry (EUROWITNESS(TM) 1.0), it allows law enforcement to "paint" physical profiles from crime-scene DNA specimens and thereby to augment or substitute for unavailable or incomplete human eye-witness testimony.

The RETINOME(TM) assay functions by measuring multiple genetic variants called Single Nucleotide Polymorphisms (SNPs), located in regions of the human genome that are involved in pigment production. The test is the first commercially available "complex" genetics test to have been developed from the knowledge provided by the recently completed human genome sequencing project. Complex genetics tests have heretofore been notoriously difficult to develop, in part because their determination is the byproduct of multiple, interacting genes and their expression is usually quantitative rather than discrete (i.e. black/white). DNAPrint`s development of innovative genome screening techniques and analytical methods enabled it to launch a service version of the test last August.

[puschlm]

ASK 0,0120
BID 0,0110

[babe_in_the_woods]

@puschlm

Vielen Dank für die Info!

Ob die News was helfen, bezweifle ich

rt 0.012

[puschlm]

... bezweifle ich leider auch ...

umsätze sind mehr als bescheiden, wird schon wieder runtergetaxt
rt 0,0110

[WOchmann]

RT gerade wieder 0,012
Bid 0,0115
Ask 0,012
Vielleicht kommt ja doch noch was, nur die Umsätze sind noch ziemlich klein
Hoffen wir das Beste
Gruß
WOchmann

[McFlying]

Die MM zihen den Kurs von alleine hoch.
Sollte tatsächlich diese Tage die erwartete news kommen, dann kommts zur Explosion und das Teil schiesst auf die 10 Cent wie letztes Jahr

[leandro01]

Moin,
wollt doch noch mal kurz vorbeischauen, ob wir die
0,003 schon erreicht haben - das wären dann schöne Einstiegskurse - und wie ich sehe, sind wir nicht mehr weit davon entfernt
Sag mal Fliegenfänger, dieser BIOM ist doch wohl nicht
plötzlich verschwunden und hat noch schnell seine Restbestände an dich verkauft ???

[hvs1]

01,

ich hoffe,daß wir die 0,003 auch nicht mehr sehen.
Habe zu 0,0095 noch einmal 1M nachgelegt.

Schau`n wir mal.

hvs1

[leandro01]

In USA sind die 0,009 gefallen.
Wir haben uns nur so lange noch um die 0,010 gehalten, weil alle noch Hoffnung auf Veröffentlichung von "News" hatten, jetzt aber die Hoffnung aufgegeben haben. Wirst sehen, jetzt geht´s im freien Fall nach unten. Sorry

[hvs1]

Obwohl ich eine Order von
0.0095 drin hatte,habe ich die 1M nicht bekommen.

hvs1

[leandro01]

Versuch dein Glück heute noch mal:
Gestern war Feiertag.

[leandro01]

hv, ich hoffe du hast dich noch nicht zum Kauf hinreissen lassen....
Tendenz weiter fallend, die 0,003 kommen bald - mind my words!

[McFlying]

Glaub ich nicht.

Sieht momentan für mich nach einem Aktientausch aus. Dann kommen news und die Rakete zündet

[leandro01]

Ein Aktientausch bei dem Volumen ?????????
Na ja, vielleicht tauschen da ein paar Studenten ihre
Haushaltskassen
Leider hat der Wert aktuell null Fantasie, der Handel schläft ein bei immer geringerem Volumen und der Kurs sinkt langsam, aber stetig.
Wenn der RS erst mal vollzogen ist, sehen wir die 0,003 - davon kannst du ausgehen.
Was dann mit dem Wert in ein paar Jahren sein wird - okay, darüber kann man reden - vielleicht sind dann sogar vom aktuellen Niveau ein paar tausend Prozent drin - aber aktuell ist hier kein Geld zu verdienen....

[babe_in_the_woods]

NEWS !

-----------------------------------------------

DNAPrint genomics Introduces New Product for Law Enforcement

23 February 2005, 10:20am ET

Ancestry Typing Kit Developed for Forensics and Crime Laboratories

SARASOTA, Fla., Feb. 23 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (BBNAP) today announced the introduction of its new DNAWitness(TM) testing kit utilizing the Company`s proprietary DNAWitness(TM) forensics technology for the law enforcement market, the only testing method available with predictive capability that can identify the percentage of a person`s genetic makeup.

"The kit is a natural progression of the Company`s DNAWitness(TM) testing service, which previously was only performed at DNAPrint`s Sarasota laboratory, and will enable forensics experts to conduct their own tests in their own facilities," stated Richard Gabriel, the Company`s President and Chief Executive Officer. "We anticipate that by making DNAWitness(TM) directly available to law enforcement agencies, the kit will lead to more rapid integration of our technology into the global forensics market and we expect it to be a significant revenue source for the Company. At the same time, we will continue to build on our established DNAWitness(TM) custom services at our own facilities to clients who prefer to outsource their DNA laboratory work."

DNAWitness(TM) forensics technology analyzes DNA recovered at a crime scene and provides the percentage of Bio-Geographical Ancestry (BGA) makeup among four possible genetic groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European, narrowing the list of potential suspects that investigators are seeking in connection with a crime.

"The kit puts the power of DNAPrint`s forensics technology directly into the hands of local crime scene investigators," stated Zach Gaskin, DNAPrint`s Technical Coordinator of Forensics. "It also is a valuable time- and cost- saving investigative tool because it reduces the number of false leads that detectives normally would have to chase. In addition, many forensics laboratories want to keep control of their crime scene samples in order to maintain a chain of custody for evidence in order to reduce challenges in court."

The kit, officially introduced on Tuesday at the American Academy of Forensic Science meeting in New Orleans, La., is the first of its kind developed for the consumable test kit market and contains all of the reagents and protocols required for forensics laboratories around the world to perform their own ancestry analysis. Proprietary on-line software systems provided by DNAPrint(TM) are expected to enable investigators to interpret their results and relate them to the likely anthropometric (physical) features of a would-be suspect by referencing DNA samples to DNAPrint`s proprietary ancestry databases.
Mentioned Last Change
DNAP 0.009 0.0002dollars or (2.17%)

The DNAWitness(TM) kit can be utilized on capillary electrophoresis (CE) instruments commonly found in forensic and university laboratories. Starting this week, the kit will be entering beta testing at select forensics laboratories. After the testing phase, which is expected to take three to four months, the Company intends to build an inventory of kits for its distributor network and its own sales force for sale to the forensics market. The Company`s testing services are available for the screening of a large number of samples or individual samples, until and even after the kit is available; investigators, forensic scientists and medical examiners need not wait until the kit is available to access this powerful new technology.

DNAPrint(TM) introduced DNAWitness(TM) technology to the law enforcement community in early 2003 and immediately gained national attention when it was credited with assisting in the apprehension of a suspected serial killer in Louisiana. It currently is aiding law enforcement agencies in more than 80 criminal investigations in the United States, United Kingdom, Australia and Canada.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .

Safe Harbor Provision

All statements in this press release that are not historical are forward- looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848

SOURCE DNAPrint genomics
-0- 02/23/2005
/CONTACT: Richard Gabriel, President and CEO, DNAPrint genomics,
[phone]; or Ron Stabiner, The Wall Street Group, Inc.,
[phone], for DNAPrint genomics/
/Web site:

http://www.dnaprint.com/

(DNAP)

CO: DNAPrint genomics
ST: Florida
IN: MTC OTC
SU: PDT TDS

DS-MR
-- FLW017 --
9829 02/23/2005 10:20 EST

http://www.prnewswire.com

[babe_in_the_woods]

RT 0.0096 9.2 Mio

[rimbick]

Zur Info:

Heute eine neue Meldung:

http://biz.yahoo.com/prnews/050223/flw017_1.html



Press Release Source: DNAPrint genomics


DNAPrint genomics Introduces New Product for Law Enforcement


Wednesday February 23, 10:20 am ET
Ancestry Typing Kit Developed for Forensics and Crime Laboratories


SARASOTA, Fla., Feb. 23 /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc. (OTC Bulletin Board: DNAP - News) today announced the introduction of its new DNAWitness(TM) testing kit utilizing the Company`s proprietary DNAWitness(TM) forensics technology for the law enforcement market, the only testing method available with predictive capability that can identify the percentage of a person`s genetic makeup.
ADVERTISEMENT


"The kit is a natural progression of the Company`s DNAWitness(TM) testing service, which previously was only performed at DNAPrint`s Sarasota laboratory, and will enable forensics experts to conduct their own tests in their own facilities," stated Richard Gabriel, the Company`s President and Chief Executive Officer. "We anticipate that by making DNAWitness(TM) directly available to law enforcement agencies, the kit will lead to more rapid integration of our technology into the global forensics market and we expect it to be a significant revenue source for the Company. At the same time, we will continue to build on our established DNAWitness(TM) custom services at our own facilities to clients who prefer to outsource their DNA laboratory work."

DNAWitness(TM) forensics technology analyzes DNA recovered at a crime scene and provides the percentage of Bio-Geographical Ancestry (BGA) makeup among four possible genetic groups -- Sub-Saharan Africa, Native American, East Asian and Indo-European, narrowing the list of potential suspects that investigators are seeking in connection with a crime.

"The kit puts the power of DNAPrint`s forensics technology directly into the hands of local crime scene investigators," stated Zach Gaskin, DNAPrint`s Technical Coordinator of Forensics. "It also is a valuable time- and cost- saving investigative tool because it reduces the number of false leads that detectives normally would have to chase. In addition, many forensics laboratories want to keep control of their crime scene samples in order to maintain a chain of custody for evidence in order to reduce challenges in court."

The kit, officially introduced on Tuesday at the American Academy of Forensic Science meeting in New Orleans, La., is the first of its kind developed for the consumable test kit market and contains all of the reagents and protocols required for forensics laboratories around the world to perform their own ancestry analysis. Proprietary on-line software systems provided by DNAPrint(TM) are expected to enable investigators to interpret their results and relate them to the likely anthropometric (physical) features of a would-be suspect by referencing DNA samples to DNAPrint`s proprietary ancestry databases.

The DNAWitness(TM) kit can be utilized on capillary electrophoresis (CE) instruments commonly found in forensic and university laboratories. Starting this week, the kit will be entering beta testing at select forensics laboratories. After the testing phase, which is expected to take three to four months, the Company intends to build an inventory of kits for its distributor network and its own sales force for sale to the forensics market. The Company`s testing services are available for the screening of a large number of samples or individual samples, until and even after the kit is available; investigators, forensic scientists and medical examiners need not wait until the kit is available to access this powerful new technology.

DNAPrint(TM) introduced DNAWitness(TM) technology to the law enforcement community in early 2003 and immediately gained national attention when it was credited with assisting in the apprehension of a suspected serial killer in Louisiana. It currently is aiding law enforcement agencies in more than 80 criminal investigations in the United States, United Kingdom, Australia and Canada.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. uses proprietary human genome research methods to develop genomic-based services and products. The Company`s ANCESTRYby DNA(TM) is a consumer product for individuals interested in learning their family heritage. DNAWitness(TM) is a forensics market tool for analyzing DNA evidence recovered at a crime scene. DNAPrint is also developing products in the pharmacogenomic market including OVANOME(TM), a genomic-based diagnostic tool that matches ovarian cancer patients with the most suitable form and dose of chemotherapy, and STATINOME(TM), a test for the cardiac drug market to determine whether patients will be good or poor responders to statins, which are effective in cholesterol reduction. For more information about the company, please visit http://www.dnaprint.com .

Safe Harbor Provision

All statements in this press release that are not historical are forward- looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`s products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`s expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848




--------------------------------------------------------------------------------
Source: DNAPrint genomics

[rimbick]

Sorry,

babe_in_the_woods war schneller als ich!


rimbick

[babe_in_the_woods]

RT 0.010 12.2 Mio

[babe_in_the_woods]

@rimbick

macht nichts!

aber trotzdem Danke

RT 0.0109

[babe_in_the_woods]

RT 0.0118 15 Mio

+28%

[rimbick]

@ hvs1

Hast Du Deine 1 Millionen Shares für 0,0095 bekommen???

Dann Glückwunsch...

rimbick

[McFlying]

[leandro01]

Glückwunsch ????????
Was wir hier heute sehen, ist ein kurzes Strohfeuer....
Schlußkurs heute: 0,009 - 0,010!
Wer kann und noch nicht zu hoch im minus sitzt, sollte heute die Chance nutzen schnell zu verkaufen, bevor es wieder abwärts geht..

[Bioexp]

Hi all!
Das war erst der Anfang!Wer jetzt nicht kauft ist selber
schuld.

[McFlying]

Leandro

Unter 5 cent geht hier nichts raus bei mir

[Bioexp]

@leandr.
hast vergessen nachzukaufen oder hast Angst das sie
explodiert!!!!!!!!!!

[McFlying]

Übersetzt mit Langenscheidt





DNAPrint-genomics Einführt Neues Erzeugnis für Gesetzes-Durchsetzung den Mittwoch den 23. Februar, 10:20 bin ET Ancestry Typing Kit Developed für Forensics und Verbrechens-Labore


SARASOTA, Fla., der Feb. 23 /PRNewswire-FirstCall/ -- DNAPrint-genomics, Inc. (OTC Bulletin Board: DNAP - Nachrichten) heute bekanntgegeben die Einführung seines neuen DNAWitness(TM) Prüfungsausstattung, die das eigene DNAWitness(TM der Gesellschaft ausnutzt) forensics-Technologie für den Gesetzesdurchsetzungsmarkt, das einzige vorhandene Prüfverfahren mit prophezeiender Möglichkeit, die den Prozentsatz der genetischen Schminke einer Person identifizieren kann.
ANZEIGE


"Die Ausstattung ist ein natürlicher Verlauf des DNAWitness(TM der Gesellschaft) Prüfungsdienstleistung, den früher war ausgeführt nur am Sarasota-Labor von DNAPrint, und wird forensics-Fachleute ermöglichen ihre eigenen Prüfungen in ihren eigenen Einrichtungen durchzuführen", angegebener Richard Gabriel, der Präsident der Gesellschaft und Hauptsächlicher Exekutiver Offizier. "Wir nehmen vorweg daß durch das Machen von DNAWitness(TM) direkt vorhanden zu Gesetzesdurchsetzungsagenturen, wird die Ausstattung zu mehr rascher Integration unserer Technologie in den globalen forensics-Markt führen und wir erwarten es daß man eine bedeutende Einkünftequelle für die Gesellschaft ist. Gleichzeitig werden wir fortfahren auf unserem bestandenen werdend DNAWitness(TM aufzubauen) Sittendienstleistungen an unseren eigenen Einrichtungen zu Kunden, die outsource ihrer DNS vorziehen, Laborarbeit.

DNAWitness(TM) forensics-Technologie analysiert an einer Verbrechensszene wiedergewonnene DNS und beschafft den Prozentsatz Biogeographischer Abstammung (BGA) Schminke unter vier möglichen genetischen Gruppen -- untersaharan Afrika, Einheimischer Amerikaner, ostasiatisch und Indoeuropäer, verengend die Liste von potentiellen Verdächtigen daß Untersuchungsbeamte in Verbindung mit einem Verbrechen suchen.

"Die Ausstattung stellt die Macht der forensics-Technologie von DNAPrint direkt in die Hände von lokalen Verbrechensszenen-Untersuchungsbeamten", angegebener Zach Gaskin, der Technische Koordinierer von DNAPrint von Forensics. "Es ist auch ein wertvoll die Zeit messen- und Kosten- Einsparung Forschungswerkzeug weil es die Anzahl von nicht wahrem Blei reduziert, das Detektive normalerweise jagen müßten. Außerdem wollen viele forensics-Labore Kontrolle ihrer Verbrechensszenenproben behalten, um eine Kette von Gewahrsam zu bewahren, da Beweis, um sich zu reduzieren, in Gericht in Frage stellt.

Die Ausstattung, führte offiziell am Dienstag an der amerikanischen Akademie von Gerichtsmedizinischer in New Orleans, La., zusammentreffender Wissenschaft ein, die erste seiner Art wird für den verzehrbaren Prüfungsausstattungsmarkt entwickelt und enthält alle Reagenzien und Protokolle benötigten für forensics-Labore um die Welt, um ihre eigene Abstammungsanalyse auszuführen. Eigene online Softwaresysteme sicherten sich von DNAPrint(TM) werden erwartet ihre Ergebnisse bewertende und sie auf die wahrscheinlichen anthropometric (körperlich) Merkmale beziehende Untersuchungsbeamte zu befähigen von ein werd-sein verdächtig von Verweis-DNS-Proben zu den eigenen Abstammungsdatenbanken von DNAPrint.

Das DNAWitness(TM) Ausstattung kann auf kapillarem electrophoresis (CE) üblicherweise herein gerichtsmedizinisch gefundene Instrumente und Universitätslabore ausgenutzt werden. Beim Anfangen dieser Woche, wird die Ausstattung Beta betreten, das bei auserlesenen forensics Labore prüft. Nach der Prüfungsphase, von der man erwartet, daß sie drei zu vier Monaten nimmt, hat die Gesellschaft vor, ein Inventar von Ausstattungen für sein Verteilernetz und sein eigenes Verkaufspersonal zu verkaufen zum forensics-Markt zu bauen. Die Prüfungsdienstleistungen der Gesellschaft sind vorhanden für die Durchleuchtung einer Vielzahl von Proben oder individuellen Proben, bis und sogar nachdem die Ausstattung vorhanden ist; Untersuchungsbeamte, gerichtsmedizinische Wissenschaftler und medizinische Prüfer müssen nicht warten, bis die Ausstattung vorhanden ist, um auf diese mächtige neue Technologie zuzugreifen.

DNAPrint(TM) eingeführtes DNAWitness(TM) Technologie zur Gesetzesdurchsetzungsgemeinschaft in frühem 2003 und erwarb sofort nationale Aufmerksamkeit als es damit gutgeschrieben wurde, bei den Sorgen eines verdächtigten seriellen Mörders in Louisiana zu helfen. Es hilft gegenwärtig Gesetzesdurchsetzungsagenturen herein mehr als 80 kriminelle Untersuchungen in den Vereinigten Staaten, Vereinigtem Königreich, Australien und Kanada.

Über DNAPrint-genomics, Inc.

DNAPrint-genomics, Inc. Verwendungen eigene menschliche genome-Forschungsmethoden, um genomic-basierte Dienstleistungen und Erzeugnisse zu entwickeln. Das ANCESTRYby-DNA(TM der Gesellschaft) ist ein Verbrauchererzeugnis für Individuen interessierte beim Lernen ihres Familienerbes. DNAWitness(TM) ist ein forensics-Marktwerkzeug für an einer Verbrechensszene wiedergewonnenen analysierungs-DNS-Beweis. DNAPrint entwickelt auch Erzeugnisse im pharmacogenomic-Markt einschließlich OVANOME(TM), ein genomic-gestandenes diagnostisches Werkzeug, das ovarian Krebspatienten an die am meisten geeignete Form und Dosis von Chemotherapie, und STATINOME(TM anpaßt), eine Prüfung für den Herzdrogenmarkt zu bestimmen ob Patienten gute oder arme Beklagten sein werden nach statins, die wirksam in Cholesterinherabsetzung sind. Besuchen Sie für mehr Auskunft über die Gesellschaft bitte http://www.dnaprint.com .

Sichere Hafen-Bereitstellung

Alle Aussagen in dieser Pressemitteilung, die nicht historisch sind, sind schicke- Aussehaussagen, die abhängig von Risiken und Ungewißheiten sind, die eigentliche Ergebnisse verursachen könnten um sich materiell von jenen geplanten zu unterscheiden, einschließlich, aber beschränkt nicht zu, Ungewißheiten, bezüglich daß Technologien, Erzeugnisentwicklung, herstellen, Marktannahme, Kosten und Preisbestimmung der Erzeugnisse von DNAPrint, Abhängigkeit von collaborations und Partnern, regulative Zustimmungen, Wettbewerb, geistiges Eigentum von anderen, und Patentschutz und Prozeß. DNAPrint-genomics, Inc. ausdrücklich verleugnet Verpflichtung oder Unternehmung öffentlich Updates oder Überarbeitungen zu schick-aussehenden Aussagen, enthalten um hierin Änderung von den Erwartungen von DNAPrint mit Hinsicht dazu widerzuspiegeln, oder Änderung von Ereignissen, Zuständen, oder Umständen, auf die ein solche Aussagen basieren, freizugeben.

Gesellschafts-Kontakt:
Richard Gabriel President und CEO 941-366-3400 -oder- Ron Stabiner Die Wall Street-Gruppe, Inc.

[McFlying]

Hr. Ray Prescott sagte, CEO von VOXBOX: "Unser von diesem Punkt an zielen ist aggressiv in unserem Vertrieb zu sein und eine bedeutende Abonnentenbasis innerhalb des ersten Jahres zu erreichen. Mit Wiederverkäufer Programme underway vermarktend, wie den asiatischen Spezialitätssprecher zu sichern, mit dem wir in Diskussionen sind, hoffen wir Tausende von Benutzern in einem relativ schnellen Zeitraum zu erreichen.

[McFlying]

Es geht wieder up

bid 0,0117-0,0118

[McFlying]

350k at ask

[McFlying]

und wieder 258k

[McFlying]

Level II Quotebook
Time MMID Size Bid
11:27 SCHB 50 0.011
10:48 GVRC 50 0.011 ↑
11:21 TDCM 50 0.011 ↑
10:38 VIEW 50 0.010 ↓
10:34 JEFF 50 0.0099 ↑
10:50 BAMM 50 0.0099
10:34 SBSH 50 0.0094
10:33 PUGS 50 0.009 ↑
10:36 VFIN 50 0.009
10:43 HDSN 50 0.009
11:26 NITE 50 0.009
10:20 DOMS 50 0.0082 ↓
07:30 FRAN 50 0.0081
07:30 HILL 50 0.0081
07:30 SACM 50 0.0081
07:30 MAXM 50 0.0081
07:56 BEST 50 0.0081 ↓
10:09 VERT 50 0.008 ↓
10:41 AGIS 50 0.008
07:30 RCAP 50 0.0075
07:30 TASL 50 0.007
07:30 FLCR 50 0.005
10:47 PERT 50 0.005 ↓
07:30 STCS 50 0.001
07:30 SEAB 50 0.001
07:30 VNDM 50 0.001
07:30 BMIC 50 0.001
08:13 CRWN 0 0.000 ↓
07:30 DATA 0 0.000
11:32 GNET 0 0.000 ↓
Ask Size MMID Time
↓ 0.011 50 SCHB 11:27
↓ 0.012 50 NITE 11:26
0.012 50 VNDM 07:30
↑ 0.012 50 VFIN 10:36
0.012 50 PERT 10:47
0.013 50 MAXM 07:30
↓ 0.013 50 BEST 07:56
↑ 0.013 50 BAMM 10:50
0.013 50 TDCM 11:21
↑ 0.013 50 PUGS 10:33
0.013 50 VIEW 10:38
↑ 0.013 50 AGIS 10:41
↑ 0.013 50 HDSN 10:43
0.014 50 BMIC 07:30
0.014 50 GVRC 10:48
0.015 50 HILL 07:30
0.015 50 DOMS 10:20
↑ 0.015 50 SBSH 10:34
0.018 50 SACM 07:30
0.018 50 TASL 07:30
0.019 50 SEAB 07:30
0.02 50 FRAN 07:30
0.02 50 RCAP 07:30
0.02 50 FLCR 07:30
0.02 50 VERT 10:09
0.02 50 JEFF 10:34
1.01 5 STCS 07:30
0.000 0 GNET 11:32

[McFlying]

" DNAPrint ist auch Entwickelerzeugnisse im pharmacogenomic-Markt einschließlich OVANOME(TM), ein genomic-gestandenes diagnostisches Werkzeug, das ovarian Krebspatienten an die am meisten geeignete Form und Dosis von Chemotherapie, und STATINOME(TM anpaßt), eine Prüfung für den Herzdrogenmarkt zu bestimmen ob Patienten gute oder arme Beklagten sein werden nach statins, die wirksam in Cholesterinherabsetzung sind.

[McFlying]

Bid 0,0118

EXPLOSIV

[McFlying]

400k zu 0,0119

[McFlying]

[McFlying]

Level II Quotebook
Time MMID Size Bid
11:58 GNET 50 0.012 ↑
11:58 SCHB 50 0.012
11:53 NITE 50 0.011 ↑
10:48 GVRC 50 0.011 ↑
11:54 TDCM 50 0.011
10:38 VIEW 50 0.010 ↓
10:34 JEFF 50 0.0099 ↑
10:50 BAMM 50 0.0099
10:34 SBSH 50 0.0094
10:33 PUGS 50 0.009 ↑
10:43 HDSN 50 0.009
11:59 VFIN 50 0.009
10:20 DOMS 50 0.0082 ↓
07:30 FRAN 50 0.0081
07:30 HILL 50 0.0081
07:30 SACM 50 0.0081
07:30 MAXM 50 0.0081
07:56 BEST 50 0.0081 ↓
10:09 VERT 50 0.008 ↓
10:41 AGIS 50 0.008
07:30 RCAP 50 0.0075
07:30 TASL 50 0.007
07:30 FLCR 50 0.005
10:47 PERT 50 0.005 ↓
07:30 STCS 50 0.001
07:30 SEAB 50 0.001
07:30 VNDM 50 0.001
07:30 BMIC 50 0.001
08:13 CRWN 0 0.000 ↓
07:30 DATA 0 0.000
Ask Size MMID Time
0.012 50 NITE 11:53
↓ 0.012 50 VFIN 11:59
0.012 50 VNDM 07:30
0.012 50 PERT 10:47
↑ 0.012 50 TDCM 11:54
↓ 0.012 50 SCHB 11:58
0.013 50 MAXM 07:30
↓ 0.013 50 BEST 07:56
↑ 0.013 50 BAMM 10:50
↑ 0.013 50 PUGS 10:33
0.013 50 VIEW 10:38
↑ 0.013 50 AGIS 10:41
↑ 0.013 50 HDSN 10:43
0.014 50 BMIC 07:30
0.014 50 GVRC 10:48
0.015 50 HILL 07:30
0.015 50 DOMS 10:20
↑ 0.015 50 SBSH 10:34
0.018 50 SACM 07:30
0.018 50 TASL 07:30
0.019 50 SEAB 07:30
0.02 50 FRAN 07:30
0.02 50 RCAP 07:30
0.02 50 FLCR 07:30
0.02 50 VERT 10:09
0.02 50 JEFF 10:34
1.01 5 STCS 07:30

[McFlying]

Heute sehen wir noch die 1,5 Cent

[McFlying]

500k at ask

[McFlying]

Tageshoch
0,012

[babe_in_the_woods]

@McFlying

die "12" und die "13" sind nicht einfach zu knacken.
währe der Hammer, wenn der Kurs die durchbrechen könnte

[McFlying]

Gnet im Ask

[McFlying]

Babe

Geht nicht, gibts nicht

[McFlying]

Ask 0,012

[McFlying]

Jetzt noch mal günstig nachladen bevor der nächste Anstieg kommt

[McFlying]

Hab noch mal nachgeladen zu 0,011

[McFlying]

Keiner mehr da

Bid 0,011 Ask 0,0118

KÄUFEN, MARSCH MARSCH

Morgen sehen wir die 5 Cent

Es sollen noch News kommen, ich gehe davon aus dasd diese Morgen kommen

[babe_in_the_woods]

RT 0.0118

[babe_in_the_woods]

@McFlying

Herzlichen Glückwunsch zu deinem Nachkauf!

[McFlying]

Dank dir

[babe_in_the_woods]

@McFlying

Muss leider weg.
Einen schönen Abend wünsch ich dir!

Bin gespannt, wie DNAP morgen eröffnen wird

[McFlying]

Babe

wünsch Dir einen schönen Abend und treibs nicht so doll

[leandro01]

Das war ja gestern ne´ Riesenexplosion
Da macht ihr so´n Wind um wieder bei 0,011 zu stehen - wo ihr vor Wochen schon gewesen seit. Kapierts doch endlich, das Ding bricht nicht nach oben aus....
Nochmal - hier sind durchaus hervorragende Chancen vorhanden sein Geld zu verzigfachen, aber eben erst auf lange Sicht....
...und nicht in ein paar Tagen

[McFlying]

Leandro

warst wohl nicht dabei

[leandro01]

Wieso "warst" ?????
War das schon eure Explosion
...bin natürlich dabei, nur aktuell im MINUS
.daher kein Grund zur Euphorie.....

[McFlying]

Viel Glück uns allen

[McFlying]

Ask bricht schon vorbörslich aus

0,011

[McFlying]

Bid zieht an

Rakete zündet

[leandro01]

McFly, dein Optimismus ist ja unermesslich....

[leandro01]

..hoffen wir mal, dass deine Rakete keine Challenger ist

[shelron]

wie is denn die kennummer oder isin?
danke

[McFlying]

US Kürzel DNAP

[McFlying]

Jetzt gehts up

0,011

[leandro01]

Streich mal die 0 nach dem Komma - dann gings UP

[McFlying]

bid 0,0109

ask

[McFlying]

Günstige Nachkaufgelegenheit

[leandro01]

[leandro01]

..das sieht mir aber heute verdächtig nach Implosion aus

[McFlying]

Sieht doch gut aus

Da haben sich einige wieder rausschütteln lassen und nun gehts wieder aufwärts

[rimbick]

Hallo,

schnell verkauft und alles ist gut...



Nun in Frankfurt:

BID: 0,007 (200.000)



r.

[leandro01]

Glückwunsch rimbick,
dann bist du ja noch passend raus.
Ich noch nicht...

[rimbick]

in FRA:

Bid: 0,008
Ask: 0,009

in US:


Market Summary 12:46:43 PM EST - Thursday, February 24, 2005 - Markets close in 3 hours and 13 minutes.
DJIA 10663.10 10.70 NASDAQ 2026.93 4.32 S&P 500 1190.18 0.62 10 Yr Bond 4.26 0.00


DNAPRINT GENOMICS - Nasdaq OTC BB: DNAP

Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size) Day Volume

0.01 0.0008 (7.41) 12:46 0.0099 (50) 0.0102 (50) 7,283,273 Latest Ticks Prev Close Open Low High Avg Day Vol
=-+= 0.0108 0.011 0.0097 0.011 4,708,800
# of Trades Last Size Avg Trade Size 52 Wk Low 52 Wk High VWAP
103 18,500 70,711 0.001 0.16 0.0101
P/E Ratio Market Cap (mil) EPS Trailing Div Yield Beta
0 8 -0.15 0.0 1.99


@ leandro01:
Verkaufe mir doch Deine billig!

r.

[leandro01]

Nö, verkaufe nicht mit Verlust....

[leandro01]

...ich sag´s doch, heute Implosion

[rimbick]

Kaufe morgen zu 0,007 in FRA!!!


DNAPRINT GENOMICS - Nasdaq OTC BB: DNAP


Exchange QuoteLast Change (%) Trade Time Bid (size) Ask (size) Day Volume

0.0097 0.0011 (10.19) 15:54 BID: 0.0097 (50) ASK: 0.0099 (50) 8,963,428


Latest Ticks Prev Close Open Low High Avg Day Vol
-=== 0.0108 0.011 0.0097 0.011 4,708,800
# of Trades Last Size Avg Trade Size 52 Wk Low 52 Wk High VWAP
136 32,000 65,908 0.001 0.16 0.0101
P/E Ratio Market Cap (mil) EPS Trailing Div Yield Beta
0 8 -0.15 0.0 1.99


Wer will seine dnap loswerden?

r.

[McFlying]

Für 5 Cent bekommst du meine

[McFlying]

[rimbick]

@ McFlying:

Du hast doch die Nullen und das Komma vergessen!!!


r.

[rimbick]

Heute nachmittag, 4:17 Uhr(US) gemeldet!!!


Form 8-K for DNAPRINT GENOMICS INC

--------------------------------------------------------------------------------

25-Feb-2005

Item 1.01 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT
As previously reported, effective September 28, 2004, the Registrant entered into an Investment Agreement (the "Biofrontera Agreement") with Biofrontera AG, a German corporation ("Biofrontera") and the shareholders of Biofrontera. Pursuant to the Biofrontera Agreement, the Registrant agreed to purchase Series B preferred shares of Biofrontera which would have given the Registrant an equity interest of approximately 51% in Biofrontera. The purchase price of the shares was 20 million Euro, payable in monthly installments of 833,333 Euro over a period of 24 months.

The transaction was conditioned upon the effectiveness of a registration statement to be filed under the Securities Act of 1933 by the Registrant with respect to a financing agreement with Dutchess Private Equities Fund, II, L.P. The Biofrontera Agreement provided that if the registration statement did not become effective on or before February 7, 2005, either party had the ability to terminate the Biofrontera Agreement without liability. The registration statement had not become effective as of such date. After discussions with Biofrontera, on February 18, 2005, the Registrant exercised its right to terminate the Biofrontera Agreement.


r.

[rimbick]

Über die Biofrontera AG

siehe auch: www.biofrontera.com








Biofrontera AG, located in Leverkusen,Germany, is establishing a specialty Pharma business, initially in the area of dermatology, where it has its leading clinical projects. It holds two wholly-owned subsidiaries, Biofrontera Pharmaceuticals GmbH in Leverkusen and Biofrontera Discovery GmbH in Heidelberg. The combined companies have about 55 employees and occupy fully equipped, modern lab facilities with sufficient space for growth at both sites. Additionally, the company has access to a 300 m² facility for animal housing at Ruhr-University Bochum.

Biofrontera Pharmaceuticals GmbH was established in 1997 in Leverkusen. The company has generated a portfolio of preclinical anti-inflammatory drugs, using molecular, cellular and in vivo pharmacology.

Biofrontera Discovery GmbH, located in Heidelberg concentrates on lead discovery and optimization based on natural product screening and derivatization. It was formed in July 2003 to acquire all assets of former bioLeads GmbH.


r.

[rimbick]

Hallo alle!!!

dnap war für mich als kurzfristiges Investment interessant! Im März `05 sollte ja der Verfall des Kurses durch die Meldung im Herbest 2004 kommen...

Habe trotzdem eine kleine Anzahl dnap gekauft und verkauft, bin sogar am Freitag ca. 19.30 Uhr zu 0,006 statt mein (Höchst-)Limit 0,007 bedient wurden!

Warum???

Um 16.25 Uhr nach Handelsschluß in den USA wurde die letzte Meldung herausgegeben!!!

Was wird in Zukunft kommen??? Bringt die Zusammenarbeit wirklich so positive Aspekte??? Könnte das Geld (20 Mio. EUR), wenn es überhaupt vorhanden ist, nicht sinnvoller bei dnap eingesetzt werden???

Ich denke, der Kurz stürzt erstmal ab! Wir werden es aber in den nächsten Tage sehen, was kommt...

Im I-Hub- und Raging Bull-Forum wird aber auch spekuliert, das heute eine andere fette Meldung kommt, die die Meldung vom Freitag aufhebt.

Gerüchteweise soll die Aktie bis auf 5 (US-)Cents steigen!!!

Egal wie es kommt, habe heute den Freitag gekauften Posten für 0,007 rausgehauen...


Allen Investierten viel Glück!

Wenn der Absturz kommen sollte und jemand verkaufen möchte: Ich habe eine 1-Mio.-Order mit Limit 0,002 in Frankfurt stehen!


r.



Hier nochmal die Meldung vom September 2004:

DNAPrint™ genomics, Inc. Agrees to Acquire Majority Ownership in German Pharmaceutical Company Biofrontera AG; Secures $35 Million Equity Commitment from Dutchess Private Equities Fund, L.P.



SARASOTA, FL, September 28, 2004, DNAPrint™ genomics, Inc. (DNAP) today announced that it has agreed to acquire a 51.77 % stake in German pharmaceutical company Biofrontera AG. DNAPrint simultaneously announced that it has received a commitment from Dutchess Private Equities Fund, L.P. to purchase up to $35 Million in DNAPrint common stock over the next two years.



DNAPrint has agreed to invest 20 Million Euro (approximately $25.00 million) over 24 months in Biofrontera Series B preferred shares (68% of B shares) representing a 51.77 % equity interest. Biofrontera will use the proceeds of the investment to advance its clinical and preclinical drug pipeline. DNAPrint is only obligated to close the transaction and to begin paying the purchase price for the Biofrontera shares after it begins making sales of common stock under its arrangement with Dutchess.



DNAPrint will participate in a clinical pipeline of novel drugs, as well as an extensive pre-clinical compound portfolio and a broad technology base. This strategic investment will form the basis of future joint ventures between the two companies, expanding DNAPrint’s presence in Europe and giving Biofrontera a presence in North America. DNAPrint and Biofrontera have signed a joint venture framework agreement designed to integrate the companies’ technologies in a mutually beneficial way.



The acquisition will transform DNAPrint from a population genomics company into a genomics based pharmaceutical company devoted to the development of 21st century “Theranostics” products. “Theranostics” blend genomics based tests with drugs as products to target segments of the patient population for enhanced efficacy and reduced side effects. Management expects the use of genome-based testing to facilitate the drug development process and accelerate selected drugs through the clinical trial process. Both DNAPrint and Biofrontera believe that Theranostics will form the foundation for post-genome, 21st century medical care.



Biofrontera’s lead product candidate, BF-Derm1, is currently in phase II clinical trials for the treatment of severe, antihistamine-refractory chronic Urticaria or chronic itching and scratching. The first interim report of a European adaptive phase II clinical trial recently indicated that the compound exhibited a 40% improvement above placebo in clinical symptoms. Biofrontera has also advanced a novel prophylactic migraine treatment to pre-clinical development, and has a series of other compounds at the pre-clinical stage. Professor Doctor Hermann Luebbert, CEO of Biofrontera AG, will join the DNAPrint board of directors.



DNAPrint also has entered into an Investment Agreement with Dutchess Private Equities Fund. Dutchess will purchase common stock from DNAPrint, at times and in amounts selected by DNAPrint, up to a total investment of $35 million over the next two years. The purchase price at which Dutchess will purchase DNAPrint’s stock is based on the trading price of the stock, and the funding will begin after DNAPrint registers the common stock that it will issue in the transaction. DNAPrint anticipates that the transaction will provide it with equity to build the business of the two companies. The commitment was arranged by Athena Capital Partners.



“We are extremely excited about the alliance between DNAPrint™ and Biofrontera, and we believe we have established a reliable and trustworthy source of capital for development of both companies” said Richard Gabriel , CEO and President of DNAPrint. “Our goal for this financing, once it is completed through the registration process, is to build shareholder value beyond the inherent investment value that Biofrontera brings to the relationship. The investment brings Biofrontera’s value to over $51 Million, and we fully expect that value to increase for our shareholders if Biofrontera strikes its milestones. We hope to increase our revenues by combining the distinct businesses of the two companies and by offering services that address many of the problems in drug discovery and development. By paying for the Biofrontera shares over time we have a unique opportunity to achieve our mutual goals and objectives.”



Professor Doctor Hermann Luebbert, CEO and founder of Biofrontera, commented: "This investment is a significant
milestone for us that provides us with substantial resources we need to move our products ahead in clinical development,
and to establish the key clinical milestones which will form the basis of the future value of Biofrontera. We are excited by
the recent progress in developing our lead product BF-Derm1 for the treatment of severe chronic Urticaria, and the
proceeds of this investment should enable us to bring this promising product to the market sooner. Including DNAPrint`s
technology in our clinical studies for the selection of patients will reduce the cost of our studies and should allow more
rapid development. We consider the ability to predict the individual patient`s response to our drugs an extremely valuable
addition to our effort in serving the patients` needs. Capital from this investment will also fund the development of
Biofrontera’s other clinical and preclinical projects and will us to move towards our goal of enhanced shareholder value.”


Athena Capital Partners, Inc. in Tampa, Florida was the private merchant bank that brought Dutchess and DNAPrint together. “The chance to invest in a first rate European pharmaceutical company like Biofrontera and to share technologies and business operations makes this relationship one we had to forge. Dutchess was the obvious choice because it allows management to obtain the funding on its own timetable, dictated by the company’s needs,” said Kevin Cimino, Managing Director and Principal at Athena.



“Biofrontera brings what DNAPrint has always wanted but few companies of its size and status have ever been able to obtain – a viable drug discovery and development pipeline. I believe the value of population genomics lies in the sale of highly targeted drug/test combinations. The new DNAPrint/Biofrontera represents to me an example of the paradigm that most 21st century drug development firms should adhere to – using population genomics to develop and obtain approval for “smart” drugs targeting specific patient subpopulations with highly predictable efficacy and minimal side effects,” said Tony Frudakis, DNAPrint’s Founder and CSO. “As a scientist, I am delighted at the prospect of working with Biofrontera scientists. I believe this is the deal all DNAPrint shareholders have been waiting for – and we hope that it will put DNAPrint on the map.”


Timo Hercegfi, partner at Biofrontera`s last lead-investor Heidelberg Innovation commented: "We are very pleased to welcome DNAPrint as a new investor on board. This agreement is mutually beneficial to both Biofrontera and DNAPrint and a great endorsement of Biofrontera`s development potential. It secures not only the funding needed to create further substantial value from Biofrontera`s clinical projects but also gives us great access to DNAPrint management’s highly relevant network in the US biotech and pharmaceutical industry."



About Biofrontera



Biofrontera is aiming to become a specialty pharma business with a profound internal research capacity to extend its drug pipeline. The company is located in Leverkusen and Heidelberg, Germany. Biofrontera’s existing major investor group participated in this financing round as well, including Heidelberg Innovation, 3i Group, TechnoMedia Kapitalbeteiligungsgesellschaft Köln mbH, and Prof. Dr. Riesner, founder of Quiagen AG. Since its first financing round in 1998 Biofrontera has raised approximately € 38 million in venture capital and strategic investments.



About DNAPrint genomics, Inc.



DNAPrint genomics Inc. was founded in 2000 by Dr. Tony Frukakis. Two products currently marketed by DNAPrint™, DNAWitness™ and the ANCESTRYbyDNA™, are a direct result of focused research by the DNAPrint™ research and development team. DNAPrint uses proprietary human genome research methods, to develop pharma-predictive tests for matching patients with drugs based on their genetic constitution, and to discover disease genes for the development of new drugs. DNAPrint will continue to develop new forensic genomics and consumer genomics testing products. The Company is traded on the NASDAQ OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com.



All statements in this press release that are not historical and are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint`sTM products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrintTM genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint`sTM expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.



Media and Press Contacts

Richard Gabriel

DNAPrintTM genomics, Inc.

CEO/President

[phone]

[titin]

@rimbick:
0,002????HAHAHA...Träumer,meine bekommst du nicht!

[leandro01]

..ich sags doch : die 0,003 kommt !!!
Alle Dummgläubigen hier werden eines anderen belehrt, die Bude ist aktuell PLATT und mehr als PLATT
Hier ist ein bestes Bsp. für eine gewaltige Geldverbrennungsmaschine ....

[rimbick]

BERICHTIGUNG!!!


The registration statement had not become effective as of such date. After discussions with Biofrontera, on February 18, 2005, the Registrant exercised its right to terminate the Biofrontera Agreement.

Habe falsch übersetzt!!!

dnap hat das Recht, die Vereinbarung zu beenden, ausgeübt!!!


Aber trotzdem mal abwarten...

r.

[ZisternE]

meine worte

[shelron]

Was heißt die Bude ist platt??

Und was soll diese Meldung vom 10. Febr.: "DNAPrint Teams With Victoria Police Forensic Services Center to Win Australian ISL Grant
Thursday February 10, 8:30 am ET"!!!???

War das einfach eine Scherzmeldung od. Fasching??

Kann doch nicht sein, dass zuerst eine Vereinbarung geschlossen wird, dann gelöst, dann eine Kooperationg eingegangen wird und dann gar nichts mehr ist, oder??!!

lg

[McFlying]

Bleibt doch mal locker und wartet ab.
Tiefer wirds nicht mehr gehen

ich habe schon letzte woche geschrieben das es nach meiner Ansicht, seit wochen Aktien umgeschichtet werden.
Warum keine ahnung, hier verkauft wohl jemand seine Teile an einem anderen zu 1 Cent.
Wenn der deal durch ist, wird wohl eine HAmmer Adhoc kommen

[leandro01]

Die Bude gibt 3mrd neue Shares aus, weil keine Kohle mehr da ist.....wenn das kein Offenbarungseid ist, weiß ich es auch nicht mehr
Diese Kohle wurde eigentlich benötigt um die Kooperation mit Biofrontera anzuschieben - nun ist diese scheinbar geplatzt.
BEIDE Seiten haben dem scheinbar zugestimmt, fragt sich nur warum....
Warum sollen nun neue Shares ausgegeben werden???
Weil Löcher gestopft werden müssen um das laufende Geschäft aufrecht erhalten zu können.....
- aktuell ist die Bude PLATT, was aber nichts über die Zukunft in 2-3 Jahren aussagt...

[McFlying]

Und die zittrigen werden wieder rausgeschmissen

günstige Einstiegskurse

[McFlying]

schni, schna, schnappi, da hab ich mir wieder welche geschnappt.

Danke

[McFlying]

Und jetzt geht es wieder hoch

500k at Ask

[McFlying]

Ask 0,0095

[McFlying]

Es geht weiter hoch

[McFlying]

ask 0,0098

[McFlying]

Nach dem gestrigen Handelsverlauf haben wir im Tageshoch geschlossen.
Das sieht nach einer Erholung aus.

MACD und RSI sind am untersten Tief.
Heute noch über die 0,012

[leandro01]

McFly, die wiederholst ja gebetsmühlenartig immer die selbe Leier....
Da kommt nichts mehr, jedenfalls nicht in absehbarer Zeit.
Und wenn wir tatsächlich mal bei 0,012 schließen sollten, sind wir in spätestens 2 Tagen wieder bei 0,009

[McFlying]

Leandro

Bleib doch mal locker und warte doch ab.-

Hast du denn keine Geduld

An der OTC egal bei welchem Wert kommt mal eine Explosion. Und hier sind wir ganz nahe dran
Vergiss nur das verkaufen nicht

[leandro01]

Ich bin locker - hab´nur keine Lust auf einen Totalverlust. Erinnere dich an dein erstes Posting in diesem Thread - da waren wir bei 0,015$ - und heute bei 0,010
Das die Explosion "mal" kommt ist klar, nur von welchem Niveau aus - das ist die Frage!

[McFlying]

Ask zieht schon vorbörslich an

[McFlying]

450k at ask

[rimbick]

Das große Blutbad, aber auch die eventuellen News sind gestern ausgeblieben...

Es ging mal bergab - aber auch gleich wieder hoch!

Was ist nun Sache??? Wie geht es weiter?

r.

[leandro01]

Na, gehts gleich wieder los mit "starken Käufen aus dem Ask" ??? und heut´noch die 0,015

[McFlying]

Leandro

Du sprichst mir aus der Seele

[McFlying]

Auf einen dunkelgrünen Tag

Ich warte immer noch auf die Hammer Pr

Wird langsam Zeit das das Teil über die wolken fliegt

[McFlying]

Ask bricht aus

Und das schon vorbörslich

Kommt gleich ne Pr

[McFlying]

Bid zieht auch nach

[McFlying]

Ask 0,0095

ziehhhhhhhhhhhhhhhhhhhhhhhh

[McFlying]

bid 0,0094

[McFlying]

Ask 0,01

[McFlying]

Was geht da ab

1,5Mio at Ask

Danach noch mal 450000 at Ask

Kaufen da schon die Insider

Das kann kein Zufall sein, hier ist was im Busch

[leandro01]

Hier geht natürlich mal wieder nix
Der Busch brennt - aber ab in Richtung 0,003

[McFlying]

Leandro

Gleich brennt was anderes

Bliev locker, das baby wird erwachsen und wird uns belohnen

[leandro01]

McFly, wenn wir im ersten Halbjahr 05 noch deine anvisierten 0,15 sehen, spendier ich ne´Kisten Schampus......Mein Wort drauf!

[McFlying]

Ok, Hand drauf und wenn nicht, dann geh wir trotzdem einen kippen. Dann gehts auf mich

Ich besorg uns noch zwei Schnecken

[McFlying]

Hallo,

gibt es neuigkeiten bezüglich DNAP

[McFlying]

Ask bricht aus

Jetzt müssen wir mal langsam explodieren

[McFlying]

Los jetzt

[babe_in_the_woods]

Mc musst nicht rot werden

[McFlying]

Langsam werde ich nervös

Das heist nicht das ich verkaufe, sondern das ich evtl. nachkaufe zu diesen Schleuderpreisen

[leandro01]

...mcfly, behalt noch ein bißchen Kohle zurück - denk an die Schnecken, die sind bestimmt nicht billig

[McFlying]

Die sind umsönst

[leandro01]

..so - bald ist die 0,008 dran - und dann der freie Fall

[McFlying]

Ask 0,0095

[leandro01]

Die 0,008 sind heute fast erreicht worden...
Sind die erst mal geknackt, dann gehts frei nach unten.
Weiß eigentlich jemand, wann die neuen Aktien den Markt überspülen werden....

[McFlying]

Hallo Liebe Leute

Ask zieht schon mal vorbörslich an

[leandro01]

McFly, auch wieder da.....
Das "ask"-Spielchen kennen wir ja schon

[McFlying]

Ja, weiss ich ja,

aber irgendwann muss das Teil doch explodieren

Ich bin guter Hoffnung

[leandro01]

Ja, irgendwann.........

[babe_in_the_woods]

Nachkaufgelegenheit!

kaufe nochmals nach, 200k zu 0.0086 USD

[leandro01]

...Geldverbrennungsgelegenheit

[babe_in_the_woods]

...Geldvervielfachungsgelegenheit

[leandro01]

Yep
Die 0,008 sind durch - der Letzte macht das Licht aus

[lvlover]

mcfly,
jeder hat schon mal lehrgeld gezahlt, das ist nicht schlimm.
es ist schlimm, hinter ner toten sache herzulaufen, das bringt nix.

es gibt werte, in du investieren solltest, verkauf den dnap-müll, wirste nicht glücklich mit.
grüße

[leandro01]

..endlich mal einer, der klar sieht

[McFlying]

Mover

Vergiss es

Jetzt wo es erst richtig losgeht

[rimbick]

Was ist los?

Ohne (schlechte) News fällt der Kurs durch kleinste Umsätze!!! Sind das keine Kaufkurse???

In Deutschland mal 20.000, mal 35.000 Aktien gehandelt, in USA einmal sogar nur 200.

200 x 0,0075 = 1,5 US$ = 1,12 EUR !!!


2:30:34 PM Trade 0.0075 5000
2:30:10 PM Trade 0.0075 10000
2:29:18 PM Ask 0.0075 5000

1:55:44 PM Trade 0.0075 200 !!!!!!!!!!!!!

1:55:24 PM Trade 0.008 25000
1:43:44 PM Trade 0.0079 33000

Wird versucht, so den Kurs zu drücken???

r.

[leandro01]

Falls es einen interessiert:
Bin jetzt raus
Hab umgeschichtet in IVK 863324, da sind wirklich und sicher 1000 % drin.
Mcfly und Co. - wünsch euch viel Glück und Erfolg
Gruß
Leo

[McFlying]

Schade leandro

Hätte dir es gegönnt den hype mitzuerleben

Trotzdem viel Glück bei deiner neuen Perle

[Pushi2]

Schau Dir mal die aktuelle Marktkapitalisierung an.
Und auf neue Aktien brauchtst Du vermutlich auch nicht mehr zu warten. Die Kriterien für den Deal sind nicht erfüllt.
Glück gehabt, keine weitere Verwässerung;-)))
Pech gehabt, kein Biofrontera-Deal;-))) und keine Phantasie;-)))
Naja, vielleicht kaufe ich bei 0.001 USD mal 1-2 Mio. shares. Vielleicht gibt es dann Ende des Jahres mal ein Gerücht, welches genügt, den Einsatz tatsächlich zu vervielfachen.
Dann heisst es aber nicht wie raus.
Und den Zockereinsatz sollte man von vorne herein abschreiben.
Alles oder nichts (und dass mit einer Erfolgswahrscheinlichkeit von ca. 2%).
Viel Spass.

[rimbick]

Wie sich der Kurs entwickeln wird, weiß niemand...

Bei einer fetten News schnellt er wieder (auf jeden Fall für kurze Zeit) nach oben!

Zumindest kurzfristig (zocken) könnte sich was machen lassen!

Im Bid FSE zu 0,005 sind zwei Blöcke: einmal 430.000 und einmal 1.500.000.
Im Ask zu 0,006 350.000.

r.

[babe_in_the_woods]

Ask-Käufe on Mass zu 0.008 USD

und der Kurs tritt auf der Stelle

[McFlying]

Bid wieder im plus

Kommt heute der große Knall

[Bombenleger]

11-Mar-2005

Annual Report



ITEM 6. MANAGEMENT`S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
The following discussion and analysis should be read in conjunction with the balance sheet as of December 31, 2003 and the financial statements as of and for the years ended December 31, 2003 and 2002 included with this Form 10-KSB.


SUMMARY
Although we have been in existence for a number of years, management`s efforts to develop our business have not yet resulted in the generation of significant revenues. Initially, management`s efforts focused on developing licensing relationships from our research and development. More recently, new management has chosen to focus on increasing sales volume in the consumer market and building sales in the forensic market while continuing to develop products for introduction to the pharmacogenomics market. We continue to devote substantially all of our efforts in initiating and developing our planned principal operations. While sales of our genealogy product ANCESTRYbyDNA(TM) are increasing, our forensic product, DNAWitness(TM) has just been introduced in the marketplace. Sales of ANCESTRYbyDNA(TM) increased because the product had only been introduced in late 2002 and in 2003, we have had the opportunity to increase our customer base thereby increasing our sales. Our pharmacogenomics products are still in development and genotyping services are in the initial stage.

A priority of management throughout 2003 was to raise the capital necessary to fund the implementation of their strategic plan. Late in 2003, we successfully secured initial funding of $8,000,000. During 2003, management began to implement the strategic plan, and throughout 2004 management expects to continue to implement and refine operational procedures and controls to support future growth and development. We intend to support research and development as a vital component of our overall growth strategy. Until potential customers are familiar with our technology and products, which will come from continued research and development and proven market use, it is unlikely that we will generate significant revenue. The following discussion of our historical financial results should be read against that background.

Management plans to continue to focus on increasing sales in the market areas of forensics and genealogy and to move towards introduction of new and expanded products in these markets. We plan to continue market research within both segments to further expand our knowledge and understanding of the most efficient way to market and sell our products.

We will continue work on Ovanome, a Taxol screening diagnostic test, currently under development that could be available for physician use in late 2006 or early 2007 along with our continued efforts on other research and development projects that are underway. We will continue to explore joint venture opportunities, particularly within the pharmacogenomic segment in order to potentially expand our position within the pharmaceutical market. A major goal of our joint venture program is to seek opportunities for drug pipeline acquisition.

Internally, management will continue to develop and implement organizational policies and procedures to increase operating efficiency and move us closer toward our goal of attaining and maintaining our planned principal operations.

Our plan of operations for the ensuing twelve months includes efforts to: 1) increase sales of our existing products, ANCESTRYbyDNA(TM), DNAWitness(TM); 2) introduce new and expanded products in the genealogy and forensic markets; 3) continue promoting our genotyping services while continuing to concentrate on research and development for both our existing products and our anticipated pharmacogenomic products and services. It is anticipated that we will add additional personnel in the laboratory and in administration, as growth warrants. No significant personnel additions are expected for 2004. Capital expenditures needed for the next twelve months are discussed in this 10-KSB/A below under the section entitled "Liquidity and Capital Resources".


RESULTS OF OPERATIONS
REVENUES AND COST OF SALES

For the years ended December 31, 2003 and 2002, revenues were $709,638 and $184,551, respectively. A $525,087 increase in revenues from the prior year is a 285% increase that was primarily a result of our sales of ANCESTRYbyDNA(TM) version 2.0 to the general public, which commenced in the fourth quarter of 2002. Revenues for ANCESTRYbyDNA(TM) were approximately $477,677 for the year ended December 31, 2003. An increase in our genotyping services also contributed to our sales growth. Revenue for our genotyping services totaled approximately $218,936 for the year ended December 31, 2003. Introduction of our forensic product, DNAWitness(TM) did not significantly impact our revenues for 2003. Revenues of DNAWitness(TM), introduced in the 4th quarter of 2003, totaled approximately $8,040. Other miscellaneous revenues, including storage fees, totaled approximately $4,985 in 2003.

To date, our genotyping service customers have come to us either through client referrals or our general website. In the future, we plan to concentrate our genotyping services on specific diseases, including cancer, neurological disorders, and heart disease. By concentrating on specific diseases, we hope to develop an expertise that will attract customers in those areas requiring external assistance and additional research capacity. Through this strategy, we will continue to build our reputation as a reliable and cost effective supplier of high quality data using our UHT SNP machine.

Sales of ANCESTRYbyDNA(TM) were generated through advertising in Family Tree, a genealogy periodical, and through public exposure that we received during the year in newspapers, magazines and television. In addition, sales were generated through our various distributors and from our website www.ancestrybydna.com. Genotyping sales were generated primarily through work with universities. Forensic sales were generated through marketing to various agencies, our attendance at various trade shows and through our relationship with Lynn Peavey catalog. As stated below, because we are a development stage enterprise and our markets and sales techniques have yet to be standardized, we continue to seek the most advantageous routes to market and sell our products.

Without a significant investment in sales or marketing, we have generated considerable interest in ANCESTRYbyDNA(TM) 2.0. We have sold, on average, 13 ANCESTRYbyDNA(TM) tests per day during 2003. An average of 9.5 of those test sales have come from our website and 4 tests per day from our distributors.

Promotional efforts to date have been fruitful but sporadic. We have been featured on or in ABC`s Prime Time Thursday, the CBS Evening News with Dan Rather, The New York Times, Miami Channel 10 WPLG, UPI, US News and World Report, Popular Science Magazine, Tampa`s Fox Channel 13 News, Germany`s ZDF News Channel, The Australian Broadcasting Corporation and The Sarasota-Bradenton Herald Tribune KTTV Fox 11 in LA, ABC Tampa, Howard Stern`s radio show, PBS WEDU Sarasota, USA Today, and Dallas Morning News.

In order to build consistent sales, we have begun to implement formal sales and marketing plans, including advertising and promotional campaigns. Implementing these plans results in increased expenses for personnel, advertising, promotion, and the collateral materials associated with these programs.

Recently, we entered into a contract with the Lynn Peavey Company. Lynn Peavey Company is a well-recognized and highly respected supplier of crime scene support materials to over 17,000 police and crime laboratories around the world. Our product, DNAWitness(TM) 2.0, is now featured in the Lynn Peavey Company catalog. We also plan to work with Lynn Peavey Company personnel to establish and conduct seminars and training programs for detectives, crime laboratory personnel and crime scene personnel on DNAWitness(TM).

We anticipate an increase in marketing and sales costs throughout 2004 as we implement our marketing and sales plan to increase product awareness. We expect to incur costs for additional sales personnel, the expenses associated with trade shows and promotions, and our planned seminars and training programs.

For the year ended December 31, 2003, cost of sales increased from $73,205 (40% of revenues) in 2002 to $432,224 (61% of revenues) in 2003. Because of the small sales volume, lack of historical comparisons and its dependence on the type of testing conducted in a particular period, these results are not indicative of the margins that we may attain if our long-term goals are achieved. During 2004, we will continue to focus on increasing market awareness of our products, particularly within the consumer and forensic markets.

While we continue to improve and refine our accounting systems, we currently do not segregate product costs. We have been and continue to be a development stage company as described in Financial Accounting Standards Board Statement No. 7. We continue to devote substantially all of our efforts to initiating and developing our planned principal operations. It is expected that our pharmacogenomic products and services, once introduced, will be our major revenue generator.

Management does not manage on a product cost basis at this time. Further management does not allocate resources based on product lines. For the most part, personnel are not solely devoted to a product or a specific task. As a development stage company, personnel are required to perform a multitude of tasks including production and research and development. Revenue generation to date has not been substantial or steady enough to warrant segregation of duties. As such labor costs vary from period to period. Further we have not reached a stage where economies of scale are available to us. Production costs vary from period to period due to the level of revenue produced and research performed. It is anticipated, as stated previously, that as we move from a development stage company to an operating company, management will focus on product revenues, costs and the associated margins. As part of our effort to move towards an operating company, we continue to develop and refine our production processes for our introduced products; so that over time and as sales increase, an efficient process can be implemented and managed on an ongoing basis. In addition, we continue to work towards designing and establishing a cohesive marketing and sales effort for our introduced products. Although, both the forensic and genealogy markets have been in existence for several years, our products are new and unique to their markets and it requires market research and testing in order to arrive at the best way to present our products. We continue to test markets through primary market research and advertising. This effort is ongoing and will continue to develop as we gather information.

RESEARCH AND DEVELOPMENT EXPENSES

In 2003 and 2002, the largest component of our operating expenses was research and development costs, which consists of raw materials, laboratory supplies, equipment expense, and facilities and employment-related costs. The expenses were incurred in support of our currently available products, ANCESTRYbyDNA(TM) and DNAWitness(TM) , and for our anticipated pharmacogenomics products.

In 2003, we also conducted research for future enhancements to DNAWitness(TM) . The research included much needed sample collection for our eye and hair color studies. In addition, investigative research and studies continued on our pharmacogenomics products, including Ovanome(TM) and Statinome(TM) and a future cardiac product. Some of this research involved the acquisition and evaluation of new samples with corresponding medical histories.

For the year ended December 31, 2003, research and development costs increased from $2,195,418 in 2002 to $2,654,259 in 2003, an increase of $458,841, or 21%. This increase is primarily the result of the stock based compensation received by our Chief Scientific Officer in return for his services to us.

Because we are in the development stage of our long-term business, it is not possible to directly correlate our current research and development costs to our future costs. Our prior management did not manage on a project cost basis with respect to research and development. Current management is implementing revenue recognition and project status measures which will disclose much of the information requested. Our revenue generation to date has not been substantial or steady enough to warrant segregation of time, costs and revenue. We are a development stage enterprise with new products that are not available through competitors for forensics and genealogy. For example, many of our products and services are in the development stage, such as ANCESTRYbyDNA and DNAWitness, and the segregation of each project by its particular cost, revenue and cash flow is currently not feasible.

We will continue to support research and development as our long-term business develops and it will remain a high priority and a necessary resource to sustain future growth. We will continue to hire research and development personnel and invest in the infrastructure required to support future innovation, including equipment, supplies and other asset purchases. In order to advance our pharmacogenomic product, Ovanome(TM) , to commercialization, our development costs for this product will increase in 2004. In addition, as we move other pharmacogenomic products forward, research and development costs will likely increase proportionately.

GENERAL AND ADMINISTRATIVE EXPENSES

Another significant component of our operating expenses is general and administrative expenses. These expenses resulted from (i) accounting and other fees associated with preparing the audited financial statements and other regulatory compliance activities, (ii) legal fees associated with our patent filings and maintenance, a lawsuit against a former employee and preparation of our securities law filings, and (iii) administrative and other salaries and expenses.

For the years ended December 31, 2003 and 2002, general and administrative expenses increased $3,328,390, from $529,535 in 2002 to $3,857,925, in 2003. $1,944,507 of this increase is stock based compensation for the three top executives that were recruited during 2003. The remaining increase consists primarily of consulting expenses. The increased consulting services resulted principally from our consulting agreements with a former director and a marketing consultant.

As discussed in Research and Development expenses, we are not able to extrapolate current general and administrative costs to our future costs. As our long-term business develops, we believe our general and administrative costs will increase with revenue growth. For example, to increase sales, an increase in marketing and sales expenditures will be required to broaden and expand our market awareness and penetration. We expect all costs associated with normal marketing and sales activities to increase, including trade shows, advertising and promotion. In addition, our current facility of approximately 4,000 square feet, will not meet our growth plans and we will need to expand our facilities to accommodate new personnel, increased production and future research and development. Our general and administrative cost will rise accordingly along with the associated costs such as utilities, taxes and maintenance.

STOCK BASED SETTLEMENT EXPENSE

During 2003, Tampa Bay Financial, Inc. exercised a right to purchase 4,763,662 shares of our common stock at a price of $.05 per share. Because the fair market value of our stock was $.082 at the date they exercised their right, we have recognized $152,437 of expense, the difference between the fair market value and the exercise price. This amount has been reflected as a settlement expense as this right was granted to Tampa Bay Financial in connection with the termination of their funding agreement.

INTEREST EXPENSE

For the years ended December 31, 2003 and 2002, interest expense increased significantly from $453,247 in 2002, to $1,402,698 in 2003. During 2003, we recorded interest expense of approximately $26,000 on related party notes and certain capital leases, $5,000 on the convertible debenture and related deferred financing fee, $500,000 related to the intrinsic value associated with the convertible debt and non-detachable warrants and $872,000 for the issuance of our common stock for the payment of related party notes payable, at an agreed upon per share price which was less than the market price of our stock. We accounted for the difference between the stock issue price and the market price as interest expense. During 2002, we recorded interest expense of approximately $46,000 on the related party notes and certain capital leases and $407,000 for the issuance of our common stock for the payment of related party notes payable, at an agreed upon per share price which was less than the market price of our stock.

During 2004, we will continue to incur interest on the related party notes. The amount, however, will be less than 2003 as the outstanding balance has been reduced by our repayments on the notes and the satisfaction of $44,940 in notes held by George Frudakis repaid in cash in January 2004. George Frudakis is a shareholder of the Company and the father of our Chief Scientific Officer, Tony Frudakis. There is no other relationship between the Company and George Frudakis. We may elect to pay the remaining notes outstanding to Tony Frudakis with common stock. If we elect to do so, these payments will result in additional interest expense for the difference between the stock issue price and the market price at the date the common stock is issued. Our interest expense may also increase as a result of our convertible debenture that was entered into in late 2003. We will have a full year of interest expense and related deferred financing fee charge during 2004. There will be no additional interest expense charge related to the intrinsic value associated with the convertible debt and non-detachable warrants that are recorded.


LIQUIDITY AND CAPITAL RESOURCES
Our operating requirements generated a negative cash flow from operations as we continue to engage in testing and development of our products. Our cash used by operating activities for the year ended December 31, 2003 was $1,529,812. We also invested in equipment of approximately $14,165 and had principal payments on capital lease obligations of $78,200. The resulting cash shortfall was financed primarily through sales of common stock, the issuance of a convertible debenture and related party funding.

Based upon our current plans, we will continue to focus on increasing market awareness of our products and developing sales for our currently available products. It is difficult to predict what revenue stream, if any, they will generate. We do not expect our revenue stream to cover costs of operations in the immediate future. We anticipate that the funding from the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will fund our operating activities through 2004. If additional funding is needed, we will attempt to raise these funds through borrowing instruments or raising additional equity. Management is confident that equity financing or debt will be available to fund our operations until revenue streams are sufficient to fund operations; however, the terms and timing of such equity or debt cannot be predicted.

Our consolidated financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplate the realization of assets and liquidation of liabilities in the normal course of business. We have incurred losses since our inception, and have experienced and continue to experience negative cash flows from operations. In addition, we have working capital and stockholders` deficiencies of approximately $1,540,922 and $2,037,095 at December 31, 2003, and will continue to have ongoing requirements for substantial additional capital investment to accomplish our business plan over the next several years. Over the past two years, our operations have been funded through related party funding, sales of common stock and the issuance of a convertible debenture. We continue to experience some success generating operating revenues; however, we do not expect our revenue stream to be sufficient to cover costs of operations in the immediate future. We anticipate that the funding we expect to receive from the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will fund our operating activities through 2004. However, there can be no assurance the minimum conversions of the outstanding debenture into common stock and the related exercise of the non-detachable warrants will be exercised and/or that we will have the cash flow to meet our operating requirements. These factors, among others, indicate that we may be unable to continue as a going concern for a reasonable period of time.

Our long term needs for cash and capital beyond the 12-month horizon will depend on the availability of funding and sales growth. Our current cash expenditure rate of approximately $370,000 per month will allow us to continue operations with little or no growth. At December 31, 2003 we had received approximately $449,930 in proceeds from our agreement with La Cove Investors, Inc. It is anticipated that we will continue to receive approximately $375,000 per month up to the full amount of the agreement of $8,000,000; at current cash expenditure rates, this would supply funding for a total of approximately 21 months, ending September 2006. Current cash flow consists of salaries and wages, lease repayments, material and sample purchases for production and research and development, selling general and administrative expenses, and limited capital purchases.

Implementing our plan of operations results in increased expenses for personnel, advertising, promotion, and the collateral materials associated with these plans. Availability of funding and sales growth will determine to what extent and how quickly these plans can be implemented. Costs will vary according to timing and level of commitment. To date, management has maintained a lower level of commitment in order to preserve liquidity. A new ad has been developed and placed for ANCESTRYbyDNA and a new promotional package is being developed.

CAPITAL EXPENDITURES

During 2004, we anticipate developing the required infrastructure to realize our 2004 operational growth plan, including acquiring or leasing property, equipment and other operating assets.

We are actively seeking to acquire or lease a new building that has 15,000 to 20,000 square feet with additional expansion potential. We estimate that lease costs will be between $15 and $25 per square foot. This does not include fit out or other associated costs such as utilities, taxes and maintenance. The initial build out of 7,000 square feet is estimated at approximately $780,000 which includes laboratory, office and warehouse space. Additional costs for equipment, furniture and fixtures are estimated at $257,000. Timing of the incurrence of the expense will depend upon the length of time required to find the appropriate facility.

In addition, it is anticipated that new laboratory and computer equipment will be purchased during 2004. Computer purchases for programming, modeling and business use is estimated at $100,000 and scientific and business programs and software at $65,000. Capital expenditures for laboratory equipment are estimated at $500,000 which includes a new robotic SNP machine at a value of approximately $250,000.

RELATED PARTY TRANSACTIONS

We have entered into certain related party transactions during the year ended 2003 and 2002. See item 7 for a discussion of these transactions.

OFF-BALANCE SHEET ARRANGEMENTS

As of December 31, 2003, we have no off-balance sheet arrangements.


CRITICAL ACCOUNTING POLICIES AND RESULTS OF OPERATIONS
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that have a significant impact on the results we report in our financial statements. Some of our accounting policies require us to make difficult and subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. Actual results may differ from these estimates under different assumptions or conditions. Below, we discuss this further, as well as the estimates and judgments involved.

ASSET IMPAIRMENT

We review our long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset exceeds its fair value and may not be recoverable. In performing the review for recoverability, we estimate the future cash flows expected to result from the use of the asset and its eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) is less than the carrying amount of the asset, an impairment loss is recognized. Otherwise, an impairment loss is not recognized. Management estimates the fair value and the estimated future cash flows expected. Any changes in these estimates could impact whether there was impairment and the amount of the impairment. Since we are in the developmental stage, we do not have much history to determine our estimated cash flows. If we do not meet our targeted cash flows for our services and if the estimated disposition of the equipment is lower, this could result in a write-down of our equipment. Our equipment is very specialized equipment related to genomics research and there probably will not be a large demand for our used equipment. The amount of our net fixed assets is the amount of the maximum risk if our assumptions were not correct. Each year the assets will have higher depreciation and the maximum risk will decrease correspondingly.

ACCRUALS AND DEFERRED COMPENSATION

We estimate the various accruals we record based upon the information we have available at the time the accruals are recorded. Any changes to these estimates could impact the accrual and related expense accounts. We recorded an accrual for federal and state income taxes that we agreed to pay for various executives on stock grants based upon the information we had at the time the entry was recorded. This estimate could change based upon the actual tax that is paid by the various executives which is based upon their actual circumstances at the time they file their taxes compared to the accrual we booked based upon estimated assumptions. During 2004, the accrual for federal and state income taxes payable for various executives on stock grants decreased by approximately $50,000 based upon actual taxes paid vs. our 2003 estimated accrual. We do not anticipate this accrual changing during the rest of 2004.

ALLOCATION OF RESEARCH AND DEVELOPMENT COSTS

Prior to 2004, our research and development costs were derived by allocating certain costs based on total labor effort. The percentage of total labor effort expended on research and development was an estimate by management. During 2004, we refined our process of allocating costs by identifying and directly expensing certain costs related to research and development and allocating certain other costs based on total labor effort that is estimated by management and employees. With some of these costs, a percentage of a total purchase order price is allocated to research and development. Also during 2004, we implemented a time card process that gives us a more refined estimate of certain employees` time. We continue to refine our process of estimating specific invoice costs to research and development as well as our process of identifying time associated with research and development. These refinements to estimates could increase or decrease our income statement expense categories of research and development, cost of sales and selling, general and administrative. Over time we believe this change in allocating costs during 2004 based upon actual labor effort vs. estimated labor effort for 2003 will result in a lower allocation of administrative costs to research and development. Also, as the Company hires employees, the department in which the employee is hired will have a direct . . .

[waxweazle]

Hallo @all and @ MCFlying

BIOM GIBTS WIEDER IHR KÖNNT JA MAL FRAGEN OB ER DEN MUMM HAT HEIRZUSTELLUING ZU NEHMEN BZW.
EINFACH MAL ZU SCHREIBEN
WÜRDE UNS ALLE FREUEN!!!!!

[McFlying]

Wir haben heute den Doppelboden getestet bei 0,0065

Hab dort nochmal zugeschlagen

RSI und MACD am untersten Tief.

Es geht nun wieder up

Ich rechne nun mit News und einer EXPLOSION

[Pushi2]

Es ist so still hier ...

[tipannehmer]

Also eines verstehe ich überhaupt nicht:
monatelang wurde gepusht und das durchhaltevermögen
strapaziert. Und nu, wo man richtig kohle machen konnte
meldet sich keiner. Wohl alle vorher weich geworden...
mfg

[MrRipley]

so läuft es eben.

Manchmal auch bei mir

[McFlying]

Ich bin noch drin

habe bei 0,006 nochmal nachgelegt

[Pushi2]

Allen Zockern kann ich nur wie bisher empfehlen, Gewinne auch mal mitzunehmen. (Auch Teilrealisierungen sind nicht dumm ...)
Bereits gestern wäre fast der Handel ausgesetzt und das Delisting erfolgt.
Offizielle Version ist zwar, dass dies ein Mißverständnis beim Filing mit den Aufsichtsbehörden war.
Könnte natürlich auch sein, dass der Kurs noch mal richtig gepusht wurde, um Insidern den letzten Ausstieg zu ermöglichen ...
Macht Eure eigene Due Diligence und denkt daran, dass ihr hier einen absoluten Zockerwert vor Euch habt, der auch in den nächsten Jahren nie Geld verdienen, sondern nur verbrennen wird!
Gut sind nur diejenigen gefahren, die mit diesem Wert kurzfristig getradet haben und nicht die Jungs, die hier immer von long schreiben und für einen guten Return jetzt schon eine Verfünf-/Verzehn-/Vervielfachung benötigen.
Weiterhin viel Spass und Augen auf!

[alex1975]

@McFlying:

vielen Dank für deinen Thread! dadurch bin ich auf DNAP aufmerksam geworden und spätestens seit heute bin ich mehr als zufrieden mit dem Investment!

[corfutown]

-35% und zufrieden ???

Entweder Masochist oder Lügner .

[tipannehmer]

guten abend,
immer das selbe spiel. monatelang wird eingesammelt und
dann plötzl. ohne grund explosion. am ersten tag mit hohem
umsatz und extrem steigendem kurs verkaufen die kursmanipu-
latoren ... an die "dummen". Bei diesen otc klitschen steige
ich immer auch am ersten hypetag aus, am zweiten ist es meist
zu spät, oder am dritten ... zur sicherheit immer am ersten tag,
und nicht ärgern über vielleicht verschenkte % am dritten ..
mfg

[corfutown]

Nehme mein voriges Posting wegen Unaktualität zurück !

[alex1975]

corfu:

ich bin aktuell nach kursrutsch immer noch mit 45% im plus mit meiner position - so schlimm ist das nicht!

aber ich gebe dir recht: gestern war ich zufriedener

[alex1975]

+25% !!

wieder mehr zufrieden...

[corfutown]

Würdest du an meiner Stelle zu dem heutigen Kurs einsteigen ?

Bin stark am Grübeln .

[alex1975]

hmm... durchaus schwierig - wenn ich noch nicht drin wäre, würde ich vermutlich mal ne KLEINE position kaufen.

ich bin zwar im plus, aber mein PERSÖNLICHES Kursziel liegt bei 0,03 - 0,04 (wenn schon OTC, dann muss es sich auch lohnen).

was mich zuversichtlich stimmt ist der dreh von minus ins fette plus gestern. auch schon vor dem 100% Tag ging es ordentlich hoch - und gestern abend dann nach dem drehen ins plus diese MASSIVEN Käufe - irgendwas scheint hier m busch zu sein, sonst wären wir unter 0,01.

ist meine meinung, wünsche dir auf jeden fall erfolg!

alex

[tipannehmer]

einfacher geht es nicht:
WIEDER EINKAUFEN
mfg

[alex1975]

genauso so ist es: 0,013 +20% !

[alex1975]

bzw. 0.0135 +25%

[alex1975]

0.014 +29,63%

[jenbroke]

Geht wohl mal wieder was

[alex1975]

jau, hier geht was: bereits 10.000.000 stücke in der ersten handelsstunde umgesetz - 0,0145 +16,94% !!!

[alex1975]

sehr geil: 0,016 +29% über 15.000.000 stücke...!!!

[MichiMischtMit]

Ich habe auch mal 10.000 Stück kostet ja fast nix
Nur 90 €

[alex1975]

herzlichen glückwunsch, ist doch schon mal ein anfang !

[MichiMischtMit]

Aber ich habe nochmal 10.000 draufgelegt.
NO RISK NO FUN
Irgendwie ist doch da was im Busch.
Sagt mir mein Bauchgefühl

[alex1975]

auf jeden fall ist da was im busch, siehe mein posting #201 !! viel erfolg wünsch ich!

[jenbroke]

0,017 - wohin gehen wir? Sehen wir Kurse wieder über 0,02 Vielleicht sind Insiderkäufe im Busch

[MichiMischtMit]

[posting]16.549.152 von alex1975 am 06.05.05 17:19:00[/posting]Danke

Bei Neomedia war ich zu spät.
Aber hier vielleicht nicht